Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
SAIL-66 by Chugai Pharmaceutical for Solid Tumor: Likelihood of Approval
SAIL-66 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Solid Tumor. According to GlobalData, Phase...